AstraZeneca gets a CDSCO panel Nod To study Rilvegostomig
New Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of the Rilvegostomig (AZD2936) concentrate for solution for infusion to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator’s choice of chemotherapy […]